Podophyllotoxin Derivative B11: Experimental Data for Esophageal Cancer Treatment

Experimental data for a series of novel podophyllotoxin derivatives designed to target LAT1 transporters for esophageal cancer treatment. The dataset includes results for the lead compound B11, showing a 64.6% tumor growth inhibition in mice and a more than 4-fold improvement in tolerability compared to etoposide. The data was authored by Manwei Jia and last updated on 2026-04 14.

Use Cases

• Compare anticancer activity of novel derivatives based on tumor growth inhibition (TGI) percentages.
• Analyze drug safety profiles based on maximum tolerated dose (MTD) improvement factors.
• Model drug distribution and pharmacokinetics based on tumor and organ concentration data.
• Investigate mechanism of action based on LAT1-dependent accumulation and cytoskeleton disruption.

Strengths

• Includes specific quantitative results, such as B11 achieving 64.6% TGI versus 30.6% for etoposide.
• Reports a concrete safety improvement, with B11 showing a more than 4-fold increase in animal tolerability.
• Data is shared under a CC-BY-NC-4.0 license, allowing for non-commercial reuse with attribution.

Limitations

• Row count and column-level documentation are unknown, which may limit suitability assessment.
• The dataset is very small at 6.0 KB, indicating a limited scope of experimental results.
• Description metadata is limited; actual data quality and structure require manual inspection after download.

Provenance

Source

figshare

Collection Method

Likely contains synthesized experimental results from pharmacological studies.

Time Range

null

Freshness

Last updated 2026-04-14 08:16:51; freshness should be verified.

Geography

null